Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA) in Patients With Relapsed or Refractory Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA) in Patients With Relapsed or Refractory Solid Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Birinapant (Primary) ; Pembrolizumab (Primary)
  • Indications Carcinoma; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Mesothelioma; Oesophageal cancer; Osteosarcoma; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Medivir AB

    • Most Recent Events

    • 16 Dec 2019 Results of futility analysis (n=14, phase II) presented in a Medivir AB media release.
    • 16 Dec 2019 Status changed from recruiting to discontinued, according to a Medivir AB media release.
    • 16 Dec 2019 According to a Medivir AB media release, the independent safety committee (IDMC) for this phase II study of birinapant in combination with pembrolizumab (Keytruda) in patients with MSS colorectal cancer has performed the planned futility analysis.IDMC's recommendation is that the study should be terminated as the analysis indicates that it is unlikely that the study's objectives will be met. Medivir has therefore decided to discontinue the recruitment of patients and to end the study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top